Red Tape Slows PBS Approval
|
By Leanne Edmistone
A DRUG proven to improve the quality of life and longevity of those with mesothelioma has yet to be approved for the Pharmaceutical Benefits Scheme, despite being considered standard treatment by medical experts. Brisbane medical oncologist Rick Abraham said yesterday mounting evidence of the success of Alimta chemotherapy made it standard treatment for the "cruel, insidious" disease, but it was still being assessed by Federal Government committees. Dr Abraham, who is based at the Prince Charles Hospital, said Alimta was the only drug shown to prolong the life span of victims (by three months), drastically cut the amount of mesothelioma present in about half of patients, and improved quality of life overall. But it cost $4500 for each treatment, and the average patient needed six treatments at three-weekly intervals. "They're being punished twice ? waiting for the resolution of the James Hardie (compensation claims), and being aware the drug Alimta is licensed for use in this country, experts say its standard but it's not available on the PBS," Dr Abraham said. *** POSTED ON JANUARY 3, 2005 *** |